Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Oxervate (cenegermin-bkbj) is a recombinant human nerve growth factor (rhNGF) indicated for the treatment of neurotrophic keratitis, a rare degenerative disease that affects the corneal epithelium due to impaired corneal innervation. Oxervate supports corneal healing by promoting epithelial cell proliferation, survival, and innervation restoration. It is the first FDA-approved therapy specifically for neurotrophic keratitis and provides a non-surgical option for patients with this otherwise vision-threatening condition.
Fact Table | |
Formula | C2944H4552N786O898S16 |
License | US FDA (2018) |
Bioavailability | Topical ocular – local action, minimal systemic absorption |
Legal status | Prescription only |
Chemical Name | Cenegermin (recombinant human nerve growth factor, rhNGF) |
Elimination half-life | Topically applied – not systemically measurable |
Dosage (Strength) | 0.002% (20 mcg/mL) ophthalmic solution |
Pregnancy | Category C – Risk not ruled out |
Brands | Oxervate |
Protein binding | Not applicable (topical use) |
PubChem CID | 123886980 |
MedlinePlus | a619048 |
ChEBI | Not assigned |
ATC code | S01XA58 |
DrugBank | DB14009 |
KEGG | D11221 |
Routes of administration | Topical (ophthalmic) |
Oxervate is administered as one drop in the affected eye(s) six times daily at 2-hour intervals for eight consecutive weeks. It should be used as monotherapy or in combination with preservative-free artificial tears, if needed. Contact lenses must be removed before administration and can be reinserted 15 minutes after instillation. The solution must be stored in the refrigerator and protected from light; each weekly carton contains daily vials that should be used within 12 hours of opening.
Active ingredient: cenegermin-bkbj (0.002% or 20 mcg/mL) Inactive ingredients: methionine, trehalose dihydrate, L-arginine hydrochloride, sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate, polysorbate 20, and water for injection.
Oxervate is contraindicated in patients with:
Use with caution in patients who may be at risk of eye infection or inflammation. Contact lens wearers must follow strict guidance to avoid contamination or interference with the treatment. Delayed healing or corneal scarring may still occur in some patients, and regular follow-up with an eye care professional is recommended. Safety and effectiveness in pediatric patients under 2 years of age have not been established.
Common side effects may include:
Less common but serious effects include corneal deposits and worsening of ocular surface disease if not monitored.